TBE in Estonia

Kuulo Kutsar

E-CDC risk status: endemic

(data as of end 2022)

History and current situation

The first cases of tick-borne encephalitis (TBE) in Estonia were identified in 1949. Today, Estonia is a TBE-endemic country. A TBE-endemic area in Estonia is defined as an area with circulation of the TBEV between ticks and vertebrate hosts as determined by detection of the TBEV or the demonstration of autochthonous infections in humans or animals within the last 20 years.

Euro-Asian genotypes of TBEV – the Western or European (TBEV-EU), Siberian (TBEV-Sib), and Far-Eastern (TBEV-FE) subtypes are co-circulating in Estonia. Vectors of TBEV, the tick species Ixodes ricinus and Ixodes persulcatus, are distributed throughout the country. The high-risk season for infection coincides with the period of biological activity of ticks and lasts for 7 months from April to November, peaking in June to August. Most TBE cases are diagnosed in persons ≥60 years of age and the incidence among the rural population is 1.8 times higher than among the urban population.

Overview of TBE in Estonia

Table 1: Virus, vector, transmission of TBE in Estonia
Viral subtypes, distribution Co-circulation of European (TBEV-EU), Far-Eastern (TBEV-FE), and Siberian (TBEV-Sib) subtypes
Reservoir animals Rodents, ruminants, game
Infected tick species (%) 2011: I. persulcatus 8%, I. ricinus on mainland 0.6%–0.8% and on Saaremaa island 3.0%.
2013 whole country: I. persulcatus 4.23%, I. ricinus 0.42%.
Dairy product transmission Documented but rare

Table 2: TBE reporting and vaccine prevention in Estonia
Mandatory TBE reporting Reporting: neurologists, infectious disease specialist. Case definition

 

Clinical criteria: a person with symptoms of the central nervous system (meningitis, meningoencephalitis, encephalomyelitis, encephaloradiculitis)

Laboratory criteria for case confirmation:

At least 1 of the following:

  • TBE-specific IgM and IgG antibodies in blood
  • TBE-specific IgM antibodies in CSF
  • Seroconversion of 4-fold increase of TBE-specific antibodies in paired serum samples
  • Detection of TBE viral nucleic acid in a clinical specimen
  • Isolation of TBEV from clinical specimens. Probable case: detection of TBE-specific IgM antibodies in a unique serum sample.

Epidemiological criteria

Exposure to a common source (unpasteurized dairy product). Case classification:

  • Possible case: Not applicable
  • Probable case: a person meeting the clinical criteria and the laboratory criteria for a probable case OR a person meeting the clinical criteria and with an epidemiological link.

Confirmed case: a person meeting the clinical and laboratory criteria for case confirmation.

Other TBE surveillance Laboratory and epidemiological surveillance
Special clinical features Biphasic disease: meningitis, meningoencephalitis, or meningoencephalomyelitis. Risk groups: people who often spend time outdoors (in nature).
Available vaccines TBE vaccination by age groups in Estonia, 2018-2019

Vaccines available: ENCEPUR CHILDREN and ENCEPUR ADULTS, FSME-IMMUN and FSME-IMMUN junior

Age

2018

2019

Vaccination Revaccination Vaccination Revaccination
1 – 4 5717 4374 8253 4181
15 -17 1123 1618 897 1324
Adults 10 567 17 997 16 817 17 856
Population

(Estonia)

1 319 133 1 324 820
Age

2020

Vaccination Revaccination Vaccination Revaccination
1 – 4 8,344 3,716 5,409 2,962
15 – 17 845 1,295 630 875
Adults 16,033 14,767 11,024 13,308
Population

(Estonia)

1 328 889 1 330 068
Vaccination recommendations and reimbursement Vaccination recommendations 1998. No reimbursement; self-paid.
Vaccine uptake by age group/risk group/general population Vaccine uptake by general population (vaccinated and revaccinated): 2018 – 3.1%; 2019 – 3.7%; 2020 – 3.4%; 2021 – 2.6%
Name, address/website of TBE National Reference Center Institute for Health Development, Lab for Virology http://www.tai.ee/en/about-us/national-institute-for-health-development

Figure 1: Burden of TBE in Estonia over time


Figure 2: Age distribution of TBE in Estonia, 2005–2022

Source data
Year0-910-1920-2930-3940-4950-5960≥
200517222026232135
200614222215253142
200710151425211837
20086101114131422
200917232022322441
201018242219333451
201112202828314784
201212281227242154
20138111212141937
2014711710161122
20151011719171537
20168858181123
20171661013101121
201861231315729
2019711512121026
20202879101024
20219975131423
2022158615242347


Figure 4: TBEV-isolation and TBE cases, 2018

TBEV-isolation and TBE cases 2018

Contact:

kkutsar@hotmail.com

Citation:

Kutsar K. TBE in Estonia. Chapter 12b. In: Dobler G, Erber W, Bröker M, Schmitt HJS, eds. The TBE Book. 6th ed. Singapore: Global Health Press;2023. doi:10.33442/26613980_12b10-6

References

  1. Health Board. [website] https://www.vaktsineeri.ee/. Immunoprophylaxis of communicable diseases, 2020 report form for vaccinators. Available at https://www.vaktsineeri.ee/et/tervishoiutootajatele-vaktsineerimine. Accessed February 21, 2020.
  2. Katargina O, Russakova S, Geller J et al. Detection and characterization of tick-borne encephalitis virus in Baltic countries and Eastern Poland. PLoS One. 2013:8(5):e61375

TBE Book